کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
6185298 1254376 2013 5 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Current standards of care for chemotherapy of optimally cytoreduced advanced epithelial ovarian cancer
ترجمه فارسی عنوان
استانداردهای کنونی مراقبت از شیمی درمانی سرطان تخمدان پیشرفته اپیتلیال به طور کامل تزریق شده است
کلمات کلیدی
سرطان تخمدان، شیمی درمانی، بیماری باقی مانده مطلوب،
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی زنان، زایمان و بهداشت زنان
چکیده انگلیسی


- Platinum-taxane chemotherapy remains the standard of care for the primary treatment of optimally cytoreduced advanced epithelial ovarian cancer
- Primary intraperitoneal cisplatin-based chemotherapy has been shown to improve survival in the setting of optimal residual advanced ovarian cancer
- The role of bevacizumab in the primary anti-neoplastic drug management of optimal residual advanced ovarian cancer remains to be defined

There has been limited change in evidence-based primary chemotherapeutic management of optimal residual advanced ovarian cancer for more than a decade. The backbone of therapy remains a platinum agent (generally carboplatin) and a taxane (generally paclitaxel). Phase 3 randomized trial data provide support for the use of weekly paclitaxel in this setting (compared to the traditional every 3-week schedule) and the addition of bevacizumab as a component of primary management. Recently available data provide increasingly solid support for a role of regional platinum administration in at least a subset of patients with optimal residual advanced ovarian cancer and an important retrospective analysis has suggested a novel biomarker that may predict for the utility (or lack thereof) of this method of drug delivery.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Gynecologic Oncology - Volume 131, Issue 1, October 2013, Pages 241-245
نویسندگان
,